Background
Methods
Reagents and animals
Synthesis and characterization of HPG
Preparation of HPG-based and control solutions
Chronic rat model of PD, bodyweight and peritoneal equilibrium test (PET)
Histological analyses
Immunohistochemical analysis
Tissue preparation and RNA extraction
Microarray and ingenuity pathway analyses (IPA)
Blood chemistry
Statistical analysis
Results
Unlike PYS, HPG solution does not have specific impact on overall health status
Unlike PYS, HPG solution does not specifically attenuate PM function
Unlike PYS, HPG solution does not significantly induce morphological and structural changes of PM
Compared to PYS, HPG solution induces less VEGF expression, macrophage activation and α-SMA-expressing cell differentiation
Compared to PYS, HPG solution significantly induces less inflammatory signaling pathways and exclusively activated lipid metabolism-related pathway
Signaling pathways (total number of genes) | Control | PYS | HPG |
---|---|---|---|
B cell development (22) | 6.3 × 10−6 (+7) | 0.001 (+5) | 0.0002 (+6) |
Complement (34) | 1 × 10−6 (+8, −1) | 1 × 10−5 (+8) | 0.001 (+7) |
Cross talk between DCs and NK cells (68) | 0.001 (+4, −6) | 0.0025 (+4, −4) | 0.0016 (+5, −6) |
Granulocyte adhesion and diapedesis (145) | 0.0001 (+6, −7) | 1 × 10−11 (+18, −8) | 0.0032 (+8, −5) |
Agranulocyte adhesion and diapedesis (154) | 0.0001 (+8, −7) | 1 × 10−10 (+18, +7) | 0.004 (+10, −4) |
ICOS/ICOSL signaling in Th cells (96) | 1.3 × 10−5 (+9, −4) | 0.0032 (+6, −3) | 0.01 (+8, −2) |
Antigen presentation pathway (22) | 0.001 (+4) | 0.0032 (+4) | 0.01 (+4) |
Nur 77 signaling in T cells (43) | 5 × 10−5 (+6, −2) | NS (+2, −2) | 0.0316 (+4, −1) |
Acute phase response signaling (157) | 0.001 (+8, −4) | 1 × 10−6 (+17, −3) | 0.0316 (+9, −3) |
CD28 signaling in Th cells (106) | 1 × 10−5 (+10, −4) | 0.0126 (+7, −2) | 0.0316 (+7, −2) |
IL-17 signaling in fibroblast (23) | NS (−2) | 0.0501 (+3, −1) | 0.0315 (+1, −3) |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (27) | 0.00316 (+2, −1) | 3.2 × 10−8 (+7, −2) | NS (−2) |
IL-10 signaling (65) | NS (+2, −3) | 1 × 10−5 (+8, −3) | NS (+1, −3) |
Differential regulation of cytokine production in MΦ and Th cell (15) | NS (+1, −1) | 0.0001 (+5) | NS (−1) |
Inhibition of matrix metalloproteinase (36) | NS (+1, −1) | 0.002 (+4) | NS (+4) |
TREM1 signaling (67) | NS (+4, −1) | 0.0025 (+7, −1) | NS (+2, −1) |
IL-6 signaling (114) | NS (+1, −5) | 0.01 (+7, −3) | NS (+1, −4) |
Toll-like receptor signaling (71) | NS (+1, −1) | 0.0126 (+6, −1) | NS (−2) |
MIF-mediated glucocortical regulation (29) | NS (+1) | 0.0501 (+4) | NS (+3) |
MIF regulation of innate immunity (73) | NS (+1) | 0.0501 (+4) | NS (+3, −1) |
HMGB1 signaling (112) | NS (+1, −5) | 0.0501 (+6, −2) | NS (+1, −3) |
Signaling pathways (p value) | Up regulated genes | Down regulated genes |
---|---|---|
Complement (1 × 10
−6
) | C2, C3, C6, C4BPA, CFD, ITGB2, ITGAM, ITGAX | C7 |
B cell development (6 × 10
−6
) | HLA-DRA, HLA-DRB5, HLA-DQB1, IL7, IL7R, PTPRC, SPN | – |
CD28 signaling in Th cells (1 × 10
−5
) | HLA-DRA, HLA-DRB5, HLA-DQB1, CD247, CD3E, CD3G, GRAP2, PAK1, PTPRC, VAV1 | Calm1, FOS, PIK3C2G, PIK3R3 |
ICOs/ICOSL signaling in Th cells (1.3 × 10
−5
) | CD247, CD3E, CD3G, GRAP2, HLA-DQB1, HLA-DRA, HLA-DRB5, PTPRC, VAV1 | Calm1, CAMK2D, PIK3C2G, PIK3R3 |
Nur 77 signaling in T cells (5 × 10
−5
) | CD247, CD3G, HLA-DRA, HLA-DRB5, HLA-DQB1, CD3E | Calm1, CASP3 |
Agranulocyte adhesion and diapedesis (0.0001) | ACTC1, AOC3, CCL4, CCL9, EZR, IL18, ITGB2, MYH3 | CCL20, CD34, CLDN5, CXCL2, CXCR4, ICAM2, MMP27 |
Granulocyte adhesion and diapedesis (0.00013) | CCL4, CCL9, EZR, IL18, ITGAM, ITGB2 | CCL20, CLDN5, CXCL2, CXCR4, ICAM2, IL1R2, MMP27 |
Cross talk between DCs and NK cells (0.001) | ACTG2, HLA-DRA, HLA-DRB5, IL18 | IL6, MIBC, FSCN1, CAMK2D, ACTC1, TNFSF10 |
Antigen presentation pathway (0.001) | CIITA, CD74, HLA-DRA, HLA-DRB5 | – |
Acute phase response signaling (0.001) | AGT, C2, C3, C4BPA, IL18, KLKB1, RBP4, SERPINA3 | FOS, IL6, PIK3R3, VWF |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (0.003162) | CCL4, IL18 | IL6 |
TREM1 signaling (0.0631, NS) | CIITA, IL18, ITGAX, TLR11 | IL6 |
IL-10 signaling (0.0631, NS) | IL18, IL10RA | FOS, IL6, IL1R2 |
Differential regulation of cytokine production in MΦ and Th cell (0.1, NS) | CCL4 | IL6 |
IL-6 signaling (0.1259, NS) | IL18 | IL6, FOS, IL1R2, PIK3C2G, PIK3R3 |
HMGB1 signaling (0.1259, NS) | IL18 | IL6, FOS, PIK3C2G, PIK3R3, RHOJ |
Inhibition of matrix metalloproteinase (0.2512, NS) | THBS2 | MMP27 |
IL-17 signaling in fibroblast (0.2512, NS) | IL6, FOS | |
MIF regulation of innate immunity (0.3162, NS) | CD74 | FOS |
MIF-mediated glucocortical regulation (0.5012, NS) | CD74 | – |
Toll-like receptor signaling (1.0, NS) | IL18 | FOS |
Signaling pathways (p value) | Up regulated genes | Down regulated genes |
---|---|---|
Granulocyte adhesion and diapedesis (1 × 10
−11
) | C5AR1, CCL2, CCL4, CCL19, CCL21, CXCL13, CXCL14, CXCR2, EZR, IL1B, IL1RN, ITGB2, MMP9, MMP16, SELL, TNF, TNFRSF11B, VCAM1 | CLDN5, CXCL2, CXCR4, ICAM2, IL33, IL1RAPL1, MMP27, THY1 |
Agranulocyte adhesion and diapedesis (1 × 10
−10
) | AOC3, C5AR1, CCL2, CCL4, CCL19, CCL21, CXCL13, CXCL14, CXCR2, EZR, IL1B, IL1RN, ITGB2, MMP9, MMP16, SELL, TNF, VCAM1 | CD34, CLDN5, CXCL2, CXCR4, ICAM2, IL33, MMP27 |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (3 × 10
−8
) | CCL2, CCL4, CCR1, CCR5, IL1B, IL1RN, TNF | IL6, IL33 |
Acute phase response signaling (1 × 10
−6
) | A2M, AGT, C3, C4BPA, CFB, FGG, HP, IKBKE, IL1B, KLKB1, RBP1, RBP4, SERPINA3, SERPINE1, TNF, TNFRSF11B | IL6, IL33, RB97 |
Complement (1 × 10
−5
) | C3, C6, C4BPA, C5AR1, CFD, ITGB2, CFB, ITGAM | – |
IL-10 signaling (1 × 10
−5
) | IKBKE, CCR1, CCR5, CD14, FCGR2B, IL1B, IL1RN, TNF | IL6, IL33, IL1RAPL1 |
Differential regulation of cytokine production in MΦ and Th cell (0.0001) | CCL2, CCL4, IL1B, LCN2, TNF | – |
B cell development (0.001) | HLA-DRA, HLA-DRB5, IL7, IL7R, PTPRC | – |
Inhibition of matrix metalloproteinase (0.002) | A2M, MMP9, MMP16, TIMP1 | MMP27, TIMP4 |
Cross talk between DCs and NK cells (0.0025) | HLA-DRA, HLA-DRB5, TNF, TLR3 | IL6, IL4, FSCN1, CAMK2D |
TREM1 signaling (0.0025) | CCL2, CIITA, FCGR2B, IL1B, NLRP3, TLR3, TNF | IL6 |
ICOS/ICOSL signaling in Th cells (0.00316) | HLA-DRA, HLA-DRB5, IKBKE, ITK, PTPRC, GRAPB2 | Calm1, CAMK2D, LAT |
Antigen presentation pathway (0.00316) | HLA-DRA, HLA-DRB5, CD74, CIITA | – |
IL-6 signaling (0.01) | IKBKE, A2M, CD14, IL1B, IL1RN, TNF, TNFRSF11B | IL6, IL33, IL1RAPL1 |
CD28 signaling in Th cells (0.0126) | HLA-DRA, HLA-DRB5, PTPRC, PAK1, GRAP2, IKBKE, ITK | Calm1, LAT |
Toll-like receptor signaling (0.0126) | CD14, IL1B, IL1RN, TLR3, TNF, UBD | IL33 |
IL-17 signaling in fibroblast (0.0501) | IKBKE, CCL2, LCN2 | IL6 |
MIF-mediated glucocortical regulation (0.0501) | CD74, PLA2G2A, PLA2G5, CD14 | – |
MIF regulation of innate immunity (0.0501) | CD74, PLA2G2A, PLA2G5, CD14 | – |
HMGB1 signaling (0.0501) | VCAM1, TNFRSF11B, TNF, SERPINE1, IL1B, CCL2 | IL6, IL4 |
Nur 77 signaling in T cells (0.0631, NS) | HLA-DRA, HLA-DRB5 | Calm1, CASP3 |
Signaling pathways (p value) | Up regulated genes | Down regulated genes |
---|---|---|
B cell development (0.00016) | HLA-DRA, HLA-DRB5, IL7, IL7R, PTPRC, SPN | – |
Complement (0.001) | C2, C3, C6, C4BPA, C5AR1, CFD, ITGB2 | – |
Cross talk between DCs and NK cells (0.0016) | ACTG2, HLA-DRA, HLA-DRB5, CD83 | IL6, MIBC, FSCN1, FSCN2, CAMK2D, ACTG2 |
Granulocyte adhesion and diapedesis (0.0032) | C5AR1, CCL21, CXCL14, EZR, ITGA2, ITGB2, MMP11, VCAM1 | CCL2, CXCL2, CXCL10, CXCR4, THY1 |
Agranulocyte adhesion and diapedesis (0.004) | ACTG2, VCAM1, EZR, ITGB2, C5AR1, ITGA2, MMP11, CXCL14, CCL21, AOC3 | CCL2, CXCL2, CXCL10, CXCR4 |
ICOS/ICOSL signaling in Th cells (0.01) | CD247, CD3G, HLA-DRA, HLA-DRB5, ICOSLG, IKBKE, ITK, PTPRC | Calm1, CAMK2D |
Antigen presentation pathway (0.01) | CIITA, CD74, HLA-DRA, HLA-DRB5 | |
Nur 77 signaling in T cells (0.0316) | CD247, CD3G, HLA-DRA, HLA-DRB5 | Calm1 |
Acute phase response signaling (0.0316) | C2, SERPINA3, IKBKE, ITIH4, C3, FGG, AGT, RBP4, C4BPA | IL6, FOS, MAPK11 |
CD28 signaling in Th cells (0.0316) | HLA-DRA, HLA-DRB5, PTPRC, CD247, CD3G, IKBKE, ITK | Calm1, FOS |
IL-17 signaling in fibroblast (0.0316) | IKBKE | IL6, FOS, MAPK11 |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (0.3162, NS) | – | CCCL10, IL6 |
IL-10 signaling (0.2512, NS) | IKBKE | IL6, FOS, MAPK11 |
Differential regulation of cytokine production in MΦ and Th cells (0.5012, NS) | – | IL6 |
Inhibition of matrix metalloproteinase (0.0631, NS) | LRP1, MMP11, SDC1, THBS2 | – |
TREM1 signaling (0.5012, NS) | CD83, CIITA | IL6 |
IL-6 signaling (0.5012, NS) | IKBKE | IL6, FOS, MAPK11, CSNK2A2 |
Toll-like receptor signaling (1.0, NS) | – | FOS, MAPK11 |
MIF-mediated glucocortical regulation (0.1259, NS) | CD74, PLA2G2A, PLA2G5 | – |
MIF regulation of innate immunity (0.0794, NS) | CD74, PLA2G2A, PLA2G5 | FOS |
HMGB1 signaling (1.0, NS) | VCAM1 | IL6, FOS, MAPK11 |
Signaling pathways (total number of genes) | PYS | HPG |
---|---|---|
B cell development (35) | NS (−2) | 0.023 (−3) |
Complement (37) | NS (+2) | NS (+1) |
Cross talk between DCs and NK cells (89) | 0.0083 (+1, −4) | NS (−4) |
Granulocyte adhesion and diapedesis (177) | 1.32 × 10−6 (+11, −2) | 0.0014 (+7, −3) |
Agranulocyte adhesion and diapedesis (189) | 7.4 × 10−5 (+10, −1) | 0.0071 (+7, −2) |
ICOS/ICOSL signaling in Th cells (122) | NS (+2, −2) | 0.0063 (+3, −4) |
Antigen presentation pathway (37) | NS (−2) | NS (−1) |
Nur 77 signaling in T cells (59) | NS (+1, −1) | NS (−1) |
Acute phase response signaling (169) | 7.8 × 10−7 (+11, −2) | NS (+4) |
CD28 signaling in Th cells (131) | NS (+2, −2) | 0.0302 (+2, −4) |
IL-17A signaling in fibroblast (35) | 0.0126 (+1, −2) | NS (−1) |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (43) | NS (+1) | NS (−1) |
IL-10 signaling (68) | NS (+2, −1) | NC |
Differential regulation of cytokine production in MΦ and Th cell (18) | NS (+1) | NC |
Inhibition of matrix metalloproteinase (39) | 0.0002 (+3, −2) | NC |
TREM1 signaling (75) | NS (+1, −1) | NC |
IL-6 signaling (127) | 0.0021 (+6, −1) | NS (+3, −1) |
Toll-like receptor signaling (74) | NS (+1, −1) | NC |
MIF-mediated glucocortical regulation (33) | NS (+1, −1) | NS (+2) |
MIF regulation of innate immunity (41) | 0.0195 (+2, −1) | NS (+2) |
HMGB1 signaling (133) | 0.0389 (+4, −1) | NS (+3) |
Signaling pathways (p value) | Up regulated genes | Down regulated genes |
---|---|---|
Granulocyte adhesion and diapedesis (1.32 × 10
−6
) | SELL, VCAM1, CXCL13, CXCR2, CXCL14, CCL21, CXCL3, TNF, MMP9, CCL19, TNFRSF11B | MMP27, THY1 |
Agranulocyte adhesion and diapedesis (7.4 × 10
−5
) | SELL, VCAM1, CXCL13, CXCR2, CXCL14, CCL21, CXCL3, TNF, MMP9, CCL19 | MMP27 |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (0.4539, NS) | TNF | – |
Acute phase response signaling (7.8 × 10
−7
) | SOCS3, HP, C3, ORM1, Saa3, CFB, TNF, A2M, RBP1, FGG, TNFRSF11B | NFKBIA, CRABP1 |
Complement (0.0933, NS) | C3, CFB | – |
IL-10 signaling (0.0692, NS) | SOCS3, TNF | NFKBIA |
Differential regulation of cytokine production in MΦ and Th cell (0.2239, NS) | TNF | – |
B cell development (0.0851, NS) | – | SPN, HLA-DRA |
Inhibition of matrix metalloproteinase (0.0002) | TIMP1, A2M, MMP9 | MMP27, ADAM12, |
Cross talk between DCs and NK cells (0.0083) | TNF | HLA-DRA, CD226, HLA-E, IL4 |
TREM1 signaling (0.2818, NS) | TNF | Tlr11 |
ICOs/ICOSL signaling in Th cells (0.0912, NS) | CAMK4, PIK3C2G | NFKBIA, HLA-DRA |
Antigen presentation pathway (0.0933, NS) | – | HLA-DRA, HLA-E |
IL-6 signaling (0.0021) | SOCS3, CSNK2A1, PIK3C2G, A2M, TNF, TNFRSF11B | NFKBIA |
CD28 signaling in Th cells (0.1117, NS) | CAMK4, PIK3C2G | NFKBIA, HLA-DRA |
Toll-like receptor signaling (0.2767, NS) | TNF | NFKBIA |
IL-17 signaling in fibroblast (0.0126) | LCN2, CEBPD | NFKBIA |
MIF-mediated glucocortical regulation (0.0776, NS) | PLA2G2A | NFKBIA |
MIF regulation of innate immunity (0.0195) | NOS2, PLA2G2A | NFKBIA |
HMGB1 signaling (0.0389) | VCAM1, PIK3C2G, TNF, TNFRSF11B | IL4 |
Nur 77 signaling in T cells (0.1995, NS) | CAMK4 | HLA-DRA |
Signaling pathways (p value) | Up regulated genes | Down regulated genes |
---|---|---|
B cell development (0.0240) | – | CD80, HLA-DRA, HLA-DQB1 |
Complement (0.3006, NS) | CFD | – |
Cross talk between DCs and NK cells (0.0759, NS) | – | CD80, MICB, HLADRA, ACTC1 |
Granulocyte adhesion and diapedesis (0.0014) | CLDN5, CXCR2, ITGA2, CXCL14, CCL21, CCL11, CXCL6 | CXCL10, IL1RAPL1 |
Agranulocyte adhesion and diapedesis (0.0071) | CLDN5, CXCR2, ITGA2, CXCL14, CCL21, CCL11, CXCL6 | CXCL10, ACTC1 |
ICOS/ICOSL signaling in Th cells (0.0063) | CD80, GRAP2, HLA-DRA, PIK3C2G, ICOSLG/LOC102723996 | CD80, GRAP2, HLA-DRA, HLA-DQB1 |
Antigen presentation pathway (0.4875, NS) | – | HLA-DRA |
Nur 77 signaling in T cells (0.0891, NS) | – | CD80, HLA-DRA, HLA-DQB1 |
Acute phase response signaling (0.0813, NS) | PIK3R3, VWF, KRAS, CRABP1 | – |
CD28 signaling in Th cells (0.0302) | PIK3R3, PIK3C2G | CD80, GRAP2, HLA-DRA, HLA-DQB1 |
IL-17 signaling in fibroblast (0.4677, NS) | – | CEBPD |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (0.5395, NS) | – | CXCL10 |
IL-10 signaling (NC) | – | – |
Differential regulation of cytokine production in MΦ and Th cells (NC) | – | – |
Inhibition of matrix metalloproteinase (NC) | – | – |
TREM1 signaling (NC) | – | – |
IL-6 signaling (0.1923, NS) | PIK3R3, PIK3C2G, KRAS | IL1RAPL1 |
Toll-like receptor signaling (NC) | – | – |
MIF-mediated glucocortical regulation (0.1169, NS) | PLA2G5, PLA2G2A | – |
MIF regulation of innate immunity (0.1660, NS) | PLA2G5, PLA2G2A | – |
HMGB1 signaling (0.4246, NS) | PIK3R3, PIK3C2G, KRAS | – |
Pathways (p value) | Symbol | Entrez gene name | Fold upregulation |
---|---|---|---|
Triacylglycerol degradation (0.0158) | FAAH | Fatty acid amide hydrolase | 2.058 |
LIPE | Lipase, hormone-sensitive | 2.014 | |
LPL | Lipoprotein lipase | 4.845 | |
PNPLA3 | Patatin like phospholipase domain containing 3 | 2.602 | |
CDP diacylglycerol biosynthesis I (0.0316) | AGPAT2 | 1-acylglycerol-3-phosphate O-acyltransferase 2 | 3.65 |
CDS1 | CDP-diacylglycerol synthase 1 | 2.755 | |
GPAT3 | Glycerol-3-phosphate acyltransferase 3 | 2.103 | |
Phosphotidylglycerol biosynthesis II (non plastidic) (0.0398) | AGPAT2 | 1-acylglycerol-3-phosphate O-acyltransferase 2 | 3.65 |
CDS1 | CDP-diacylglycerol synthase 1 | 2.755 | |
GPAT3 | Glycerol-3-phosphate acyltransferase 3 | 2.103 | |
Triacyglycerol biosynthesis (0.0398) | AGPAT2 | 1-acylglycerol-3-phosphate O-acyltransferase 2 | 3.65 |
DGAT2 | Diacylglycerol O-acyltransferase 2 | 3.914 | |
GPAT3 | Glycerol-3-phosphate acyltransferase 3 | 2.103 | |
LPIN2 | Lipin 2 | 2.193 |